programa

ADVANCED
COURSE
on Oncology/Hematology
Therapy 2016
September
15•16•17
2016 Lisbon
PORTUGAL
Centro Cultural de Belém
www.hcpa.pt
September
ADVANCED
COURSE
on Oncology/Hematology
15•16•17
2016 Lisbon
PORTUGAL
Centro Cultural de Belém
Therapy 2016
LEARNING OBJECTIVES
\ To understand the basic principles of Medical Oncology
\ To understand how the main tumour types are approached in the clinic
from diagnosis to therapy
\ To get closed to the practice of Oncology in a multidisciplinary setting
\ To capture the importance of a molecular definition of tumours in
the context of a modern precision Medicine
CO-CHAIRS
Mónica
Nave
Nazaré
Rosado
The volume of oncology drug information is expanding exponentially
and the need for more emphasis on medication safety monitoring and
assurance is imperative. There is an increasing need for specialized and
well-trained oncology professionals and it is forecasted that the
demand for highly motivated and properly credentialed professional
teams in oncology will continue to increase for the foreseeable future!
This HCPA Advanced Course on Oncology/Hematology aims to
dotate professionals with the actual best practice and create opmportunities for knowledge sharing and collaboration!!
FACULTY
September
15•16•17
2016 Lisbon
PORTUGAL
Mónica
Nave
Centro Cultural de Belém
\ Oncologist at Hospital da Luz, Portugal
\ Member of the Portuguese
Medical Society (Oncology)
Portugal
Nazaré
Rosado
\ Hospital Pharmacy Specialist
- Ordem dos Farmacêuticos
\ Lead pharmacist Aseptic Service
at Hospital da Luz,
Portugal
Bruno
Silva-Santos
\ MD, PhD, Post-Doctoral
\ Vice-Director of Instituto de Medicina
Molecular
\ Associate Professor at Faculdade
de Medicina da Universidade de Lisboa
Portugal
Marta
Soares
\ MD, Medical Oncology
\ Coordenadora da Unidade de Pulmão,
\ Responsável da área médica da Unidade
de Sarcomas, IPOPORTOFG
Portugal
John
Valgus
\ John Valgus, PharmD, BCOP, CPP
\ Clinical Specialist, clinic based
- Hematology/Oncology Clinic
\ Clinical Assistant Professor
- UNC Eshelman School of Pharmacy
and UNC School of Medicine
United States
FACULTY
September
15•16•17
2016 Lisbon
PORTUGAL
Emanuel
Gouveia
Centro Cultural de Belém
\ MD, Medical Oncology
\ IPOLFG, E.P.E.
Portugal
Azucena
Aldaz
Fábio
Lopes
\ MD, Medical Oncology
\ Hospital Beatriz Ângelo, Lisboa
Portugal
\ Clinical Pharmacist
\ Clinica Universidad de Navarra
\ Grupo de Farmacia Oncológica de la SEFH
Spain
Cristina
João
\ MD
\ Haematologist at Fundação
Champalimaud, Lisboa
\ Faculdade de Ciências Médicas,
Universidade Nova de Lisboa
Portugal
Rui
Bergantim
\ MD
\ Haematologist at Hospital São João, Porto
\ PhD Student of the Cancer Drug Resistance
Group at IPATIMUP
Portugal
September
ADVANCED
COURSE
on Oncology/Hematology
15•16•17
2016 Lisbon
PORTUGAL
Centro Cultural de Belém
Therapy 2016
SCIENTIFIC
PROGRAM
DAY 1 - 15 Sep
THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH
Monica Nave, MD
Nazaré, PharmD
A PRACTICAL REVIEW OF CANCER DIAGNOSIS,
STAGING, PROGNOSIS AND THERAPY
Monica Nave, MD
SYSTEMIC ANTICANCER THERAPY: CLASSIC CHEMOTHERAPY
AND TARGETED THERAPY
Nazaré, PharmD
CANCER IMMUNOTHERAPY
Bruno Silva Santos, PhD
THERAPY MANAGEMENT ON SOLID TUMORS
NSCLC
Marta Soares, MD, PT
John Valgus, PharmD, US
\ Diagnosis and staging
\ Adjuvant and neoadjuvant setting
\ New approaches oral therapies and immunotherapy
\ Managing toxicities
\ Clinical Cases Session
September
ADVANCED
COURSE
on Oncology/Hematology
15•16•17
2016 Lisbon
PORTUGAL
Centro Cultural de Belém
Therapy 2016
DAY 2 - 16 Sep
THERAPY MANAGEMENT ON SOLID TUMORS
Melanoma
Emanuel Gouveia, MD, PT
John Valgus, PharmD, US
\ Immunotherapy and Target therapy
\ The best choice and best sequence
\ Managing symptoms and toxicities
\ Clinical Cases Session
CANCER OF UNKNOWN PRIMARY: A DIAGNOSTIC
AND THERAPEUTIC CHALLENGE
Fábio Lopes, MD, PT
ARE PARP INHIBITORS READY FOR PRIME TIME?
Mónica Nave, MD, PT
DAY 3 - 17 Sep
THERAPY MANAGEMENT ON HEMATOLOGIC MALIGNANCIES
Myelodisplasic Syndromes
Azucena Aldaz, PharmD, PhD, SP
TBA ( to be announced) , MD, US
\ Classification, features, diagnosis and treatment options
\ New molecules
\ Supportive therapy
IMMUNOTHERAPY IN HEMATOONCOLOGY
Monoclonal Antibodies, Checkpoint Inhibitors and Cart Cells
Cristina João, MD, PT
Small Molecules (Anti-BTK and Anti-PI3K),
Imunomodulation and Transplantation
Rui Bergantim, MD, PT
September
ADVANCED
COURSE
on Oncology/Hematology
15•16•17
2016 Lisbon
PORTUGAL
Centro Cultural de Belém
Therapy 2016
SCIENTIFIC COMMITTEE
Mónica Nave, MD, Hospital da luz, PT
Mª Nazaré Rosado, PharmD, Hospital da luz, PT
Fernando FernandezLlimos, FFUL, PT
ORGANISING COMMITTEE
Andreia Duarte, HCPA • Rui Rodrigues, HCPA
REGISTRATION (Limited to 30 places)
Registration values
2350 euros (VAT included)
Venue
Centro Cultural de Belém (Sala Amália Rodrigues), Lisbon, Portugal
Secretariat
[email protected]
Social events
Closure dinner on Friday, September 16th
EVENT OFFICIAL AGENCY
Perfect Experiences
RNAVT 3965
Rua da Junqueira 200 1º
1300-346
Portugal
T 213 616 720
F 213 616 729
E [email protected]
www.perfxp.com
flgx
is a brand owned by Perfect Experiences.
OUR MISSION IS
PROMOTING
EXCELLENCE
IN MEDICINES
MANAGEMENT
The central objective of HCPA is to promote
a complete training program aiming excellence,
based on the current best practices of the various
areas related to hospital medicines.
Our trainings are delivered by recognized
national and international health professionals
with proven experience.
www.hcpa.pt